News | September 13, 2021
Boehringer Ingelheim and Twist Bioscience ink antibody discovery collaboration
Research collaboration covers multiple antibody research programs
Research collaboration covers multiple antibody research programs
The company's discovery services support a wide range of global innovator companies from start-ups to large pharma companies, across a diverse set of therapeutic areas including oncology, CNS, antivirals, and inflammation among others
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Partnership combines Apexon's agentic AI platforms and cloud modernization tools with AWS infrastructure to accelerate AI deployment, clinical innovation, and digital transformation across healthcare and life sciences
Initiative seeks innovative experimental and computational approaches to uncover neural circuits regulating immune function and identify novel therapeutic targets
M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges
The collaboration is focused on overcoming a major limitation in existing cancer drugs
Collaboration integrates MERCURIUS DRUG-seq technologies with Revvity’s screening portfolio, enabling scalable transcriptomic profiling for next-generation drug discovery and AI-driven research
New facility will open by October 2026 and house 500 process development specialists
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
